Abstract:Objective: This study aimed to determine whether magnetic resonance imaging (MRI) biomarkers are associated with visual prognosis in myelin oligodendrocyte protein (MOG)-associated optic neuritis (MOG-ON). Design: Cross-sectional analysis. Subjects: Patients meeting 2023 international diagnostic criteria for MOG antibody-associated disease who were seen for first episodes of MOG-ON at three tertiary neuro-ophthalmology practices between January 2017 and July 2023 were enrolled. Patients who received less than 3 months of neuro-ophthalmic follow-up and did not demonstrate visual recovery (visual acuity [VA] ≥20/20 and visual field mean deviation [VFMD] >-5.0 dB) during this time were excluded. Methods: Patients received contrast-enhanced, fat-suppressed MRI of the brain and orbits within one month of symptom onset. Main outcome measures: The associations between radiological biomarkers and poor VA outcome (<20/40), incomplete VA recovery (<20/20), and poor VFMD outcome (VFMD <-5.0 dB) were assessed using multivariable logistic regression adjusting for time from symptom onset to treatment and nadir VA or VFMD. Radiological biomarkers included length of optic nerve enhancement (below vs. above 25%, 50%, and 75%); degree of orbital, canalicular, and intracranial or chiasmal optic nerve enhancement (mild vs. moderate-severe compared to the lacrimal gland); and absence vs. presence of optic nerve sheath enhancement on baseline T1-weighted MRI. Results: A total of 129 eyes of 92 patients (median [IQR] age 37.0 [20.8-51.3], 65.2% female) were included. Poor VA outcome was seen in 6.2% of cases, incomplete VA recovery in 19.4%, and poor VFMD outcome in 16.9%. Compared to eyes with moderate-severe enhancement, eyes with mild orbital optic nerve enhancement were more likely to have poor VA outcome (OR 8.57; 95% CI [1.85, 51.14], P=0.009), incomplete VA recovery (OR 7.31, 95% CI [2.42, 25.47], P=0.001), and poor VFMD outcome (adjusting for time to treatment: OR 6.81, 95% CI [1.85, 28.98], P=0.005; adjusting for nadir VFMD: OR 11.65, 95% CI [1.60, 240.09], P=0.04). Lack of optic nerve sheath enhancement was additionally associated with incomplete VA recovery (OR 3.86, 95% CI [1.19, 12.85], P=0.02) compared to the presence of enhancement. These associations remained consistent in subgroup logistic regression analysis of MRIs performed before initiation of treatment but were not seen in pairwise analysis of MRIs performed after treatment. Conclusions: In eyes with first MOG-ON episodes, milder enhancement in the orbital optic nerve is associated with poorer VA and VF recovery. Prospective and mechanistic studies are needed to confirm the prognostic utility of MRI in MOG-ON.

Macular vascular density alteration patterns in paediatric optic neuritis patients with serum MOG antibody positivity detected by optic coherence tomography angiography

Clinical Characteristics, Disease Course, and Outcomes of Paediatric Patients with Myelin Oligodendrocyte Glycoprotein-Ab Associated Disease: A Retrospective Clinical Study

Alterations in the Retinal Vascular Network and Structure in MOG Antibody-Associated Disease: an Optical Coherence Tomography Angiography Study.

Proteomic Profiling of Cerebrospinal Fluid in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Retinal structural and microvascular changes in myelin oligodendrocyte glycoprotein antibody disease and neuromyelitis optica spectrum disorder: An OCT/OCTA study

Alterations in the Retinal Vascular Network and Structure in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: A Longitudinal OCTA Study

The Difference of the Retinal Structural and Microvascular Characteristics in Patients with MOGAD-ON and AQP4-ON

Myelin Oligodendrocyte Glycoprotein Antibody Disease Optic Neuritis: A Structure–Function Paradox?

Structural and Functional Alterations in Visual Pathway After Optic Neuritis in MOG Antibody Disease: A Comparative Study With AQP4 Seropositive NMOSD

Comparison of Macular Structural and Vascular Changes in Neuromyelitis Optica Spectrum Disorder and Primary Open Angle Glaucoma: a Cross-Sectional Study

Comparison of the Retinal Vascular Network and Structure in Patients with Optic Neuritis Associated with Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies: an Optical Coherence Tomography Angiography Study

[Clinical Characteristics, Treatment and Prognosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis in Children].

A single-center retrospective series of OCT and MRI findings in pediatric MOGAD optic neuritis patients

Comparison of clinico-radiological profile, optical coherence tomography parameters, and outcome in MOGAD and Neuromyelitis optica spectrum disorder subtypes: A prospective observational study

Retinal structural and microvascular deterioration independent of optic neuritis in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders: An optical coherence tomography angiography study

Pattern Visually Evoked Potentials (pVEPs) and Retinal Nerve Fiber Thickness in a Japanese Girl With Anti-myelin Oligodendrocyte Glycoprotein Antibody Seropositive Optic Neuritis

Evaluation of microvascular changes in the retina and choriocapillaris in primary glaucoma and neuromyelitis optica spectrum disorder with optical coherence tomography angiography

Association of retinal microvascular abnormalities and neuromyelitis optica spectrum disorders with optical coherence tomography angiography

Radiological predictors of visual outcome in myelin oligodendrocyte glycoprotein-related optic neuritis

A Longitudinal Comparison of the Recovery Patterns of Optic Neuritis with MOG Antibody-Seropositive and AQP4 Antibody-Seropositive or -Seronegative for Both Antibodies

Frequency of Asymptomatic Optic Nerve Enhancement in 203 Patients With MOG Antibody-Associated Disease